Renalytix (RNLX) Stock Price, News & Analysis

-0.08 (-13.49%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
384,352 shs
Average Volume
293,371 shs
Market Capitalization
$39.60 million
P/E Ratio
Dividend Yield
Price Target

Renalytix MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
874.5% Upside
$5.00 Price Target
Short Interest
0.81% of Shares Sold Short
Dividend Strength
News Sentiment
-0.13mentions of Renalytix in the last 14 days
Based on 7 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Computer And Technology Sector

448th out of 599 stocks

Medical Laboratories Industry

15th out of 19 stocks

RNLX stock logo

About Renalytix Stock (NASDAQ:RNLX)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.

RNLX Stock Price History

RNLX Stock News Headlines

Renalytix AI earnings: here's what Wall Street expects
Renalytix Sells Stock to Raise Up to $4 Mln
3 Ridiculously Enticing Stocks to Buy for Under a Buck
See More Headlines
Receive RNLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$3.40 million
Book Value
$0.15 per share


Free Float
Market Cap
$39.60 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. James R. McCullough M.B.A. (Age 56)
    Chief Executive Officer
    Comp: $1.04M
  • Mr. Thomas H. McLain CPA (Age 65)
    M.B.A, President
    Comp: $662.7k
  • Mr. Oliver James Sterling III
    Chief Financial Officer
  • Mr. Fergus Fleming (Age 56)
    Chief Technology Officer
  • Dr. Michael J. Donovan M.D. (Age 69)
    Ph.D., Chief Medical Officer
  • Mr. Howard B. Doran Jr. (Age 63)
    Chief Business Officer
  • Mr. Salim Gulamabbas Hamir F.C.A.
    Company Secretary

RNLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Renalytix stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Renalytix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RNLX shares.
View RNLX analyst ratings
or view top-rated stocks.

What is Renalytix's stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Renalytix's shares. Their RNLX share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 874.5% from the stock's current price.
View analysts price targets for RNLX
or view top-rated stocks among Wall Street analysts.

How have RNLX shares performed in 2024?

Renalytix's stock was trading at $0.39 at the start of the year. Since then, RNLX shares have increased by 31.6% and is now trading at $0.5131.
View the best growth stocks for 2024 here

When is Renalytix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 26th 2024.
View our RNLX earnings forecast

How were Renalytix's earnings last quarter?

Renalytix Plc (NASDAQ:RNLX) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.70 million. Renalytix had a negative trailing twelve-month return on equity of 1,008.88% and a negative net margin of 1,687.80%. During the same quarter in the previous year, the company earned ($0.14) EPS.

What other stocks do shareholders of Renalytix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).

When did Renalytix IPO?

Renalytix (RNLX) raised $156 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel acted as the underwriters for the IPO.

Who are Renalytix's major shareholders?

Renalytix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.13%).

How do I buy shares of Renalytix?

Shares of RNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNLX) was last updated on 5/18/2024 by Staff

From Our Partners